Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu

Bioscience Reports

Volumn 29, Issue 1, 2009, Pages 35-45

  Shiu, Li Yen ^a   Liang, Chia Hua ^b   Chang, Li Ching ^c   Sheu, Hamm Ming ^d   Tsai, Eing Mei ^a,e   Kuo, Kou Wha ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Epirubicin (EPI); HER2 neu; Solamargine (SM); Topoisomerase IIa (TopoIIa); Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; BETA SOLAMARIN; BETA-SOLAMARINE; EPIRUBICIN; MONOCLONAL ANTIBODY; SOLANUM ALKALOID; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL LINE; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HUMAN; PROTO ONCOGENE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG COMBINATIONS; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; SOLANACEOUS ALKALOIDS;

EID: 64249110664     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20080028     Document Type: Article

References (42)

1. Fernandez Val, J. F., Losada, J., Arregui Murua, M. A. and Sarria, R. (2002) Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. Cancer Genet. Cytogenet. 138, 69-72
2. Sibilia, M., Steinbach, J. P., Stingl, L., Aguzzi, A. and Wagner, E. F. (1998) A strain independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17, 719-731
3. Marth, C., Lang, T., Cronauer, M. V., Doppler, W., Zeimet, A. G., Bachmair, F., Ullrich, A. and Daxenbichler, G. (1992) Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. Int. J. Cancer 52, 311-316
4. Chen, B., Peng, X., Pentassuglia, L., Lim, C. C. and Sawyer, D. B. (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol. 7, 114-121
5. Buchler, P., Reber, H. A., Eibl, G., Roth, M. A., Buchler, M. W., Friess, H., Isacoff, W. H. and Hines, O. J. (2005) Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int. J. Oncol. 27, 1125-1130
6. Baselga, J., Seidman, A. D., Rosen, P. P. and Norton, L. (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11, 43-48
7. Heintz, N. H., Leslie, K. O., Rogers, L. A. and Howard, P. L. (1990) Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. Arch. Pathol. Lab. Med. 114, 160-163
8. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792
9. Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N. et al. (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10, 5650-5655
10. Keefe, D. L. (2002) Trastuzumab-associated cardiotoxicity. Cancer 95, 1592-1600
11. Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., Murphy, M., Stewart, S. J. and Keefe, D. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20, 1215-1221
12. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G. and Slamon, D. J. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648
13. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. and Mendelsohn, J. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831
14. Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H. and Levine, M. N. (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354, 2103-2111
15. Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L. and Wolmark, N. (1998) ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90, 1361-1370
16. Hu, K., Kobayashi, H., Dong, A., Jing, Y., Iwasaki, S. and Yao, X. (1999) Antineoplastic agents, III: steroidal glycosides from Solanum nigrum. Planta Med. 65. 35-38
17. Liu, L. F., Liang, C. H., Shiu, L. Y., Lin, W. L., Lin, C. C. and Kuo, K. W. (2004) Action of solamargine on human lung cancer cells-enhancement of the susceptibility of cancer cells to TNFs. FEBS Lett. 577, 67-74
18. Liang, C. H., Liu, L. F., Shiu, L. Y., Huang, Y. S., Chang, L. C. and Kuo, K. W. (2004) Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem. Biophys. Res. Commun. 322, 751-758
19. Lin, C. N., Lu, C. M., Cheng, M. K., Gan, K. H. and Won, S. J. (1990) The cytotoxic principles of Solanum incanum. J. Nat. Prod. 53, 513-516
20. Greenwood, F. C., Hunter, W. H. and Glover, J. S. (1963) The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem. J. 89, 114-123
21. Greco, W. R., Bravo, G. and Parsons, J. C. (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385
22. Hengstler, J. G., Lange, J., Kett, A., Dornhofer, N., Meinert, R., Arand, M., Knapstein, P. G., Becker, R., Oesch, F. and Tanner, B. (1999) Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res. 59, 3206-3214
23. Piechocki, M. P., Pilon, S. A. and Wei, W. Z. (2002) Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 259, 33-42
24. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M. et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726
25. Mass, R. (2000) The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 27, 46-52
26. Archer, S. G., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I. and Robertson, J. F. (1995) Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer 72, 1259-1266
27. Dykins, R., Corbett, I. P., Henry, J. A., Wright, C., Yuan, J., Hennessy, C., Lennard, T. J., Angus, B. and Horne, C. H. (1991) Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J. Pathol. 163, 105-110
28. Rosen, P. P., Lesser, M. L., Arroyo, C. D., Cranor, M., Borgen, P. and Norton, L. (1995) Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75, 1320-1326
29. Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J. and Slamon, D. J. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15, 537-547
30. Kuo, K. W., Hsu, S. H., Li, Y. P., Lin, W. L., Liu, L. F., Chang, L. C., Lin, C. C., Lin, C. N. and Sheu, H. M. (2000) Anticancer activity evaluation of the solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem. Pharmacol. 60, 1865-1873
31. Shiu, L. Y., Liang, C. H., Huang, Y. S., Sheu, H. M. and Kuo, K. W. (2008) Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. Cell. Biol. Toxicol. 24, 1-10
32. Liang, C. H., Shiu, L. Y., Chang, L. C., Sheu, H. M., Tsai, E. M. and Kuo, K. W. (2008) Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69cells to trastuzumab and epirubicin. Chem. Res. Toxicol. 21, 393-399
33. Liang, C. H., Shiu, L. Y., Chang, L. C., Sheu, H. M. and Kuo, K. W. (2007) Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol. Nutr. Food Res. 51, 999-1005
34. Burke, P. M. and Wiley, H. S. (1999) Human mammary epithelial cells rapidly exchange empty EGFR between surface and intracellular pools. J. Cell. Physiol. 180, 448-460
35. Stoscheck, C. M. and Carpenter, G. (1984) Down regulation of epidermal growth factor receptors: direct demonstration of receptor degradation in human fibroblasts. J. Cell Biol. 98, 1048-1053
36. Stoscheck, C. M. and Carpenter, G. (1984) Characterization of the metabolic turnover of epidermal growth factor receptor protein in A-431 cells. J. Cell. Physiol. 120, 296-302
37. Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G. and Gill, G. N. (1991) The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 266, 11083-11094
38. Meyer, K. N., Kjeldsen, E., Straub, T., Knudsen, B. R., Hickson, I. D., Kikuchi, A., Kreipe, H. and Boege, F. (1997) Cell cycle-coupled relocation of types I and II topoisomerases of catalytic enzyme activities. J. Cell Biol. 136, 775-778
39. Jarvinen, T. A. and Liu, E. T. (2003) HER-2/neu and topoisomerase IIα in breast cancer. Breast Cancer Res. Treat. 78, 299-311
40. Jarvinen, T. A., Tanner, M., Rantanen, V., Barlund, M., Borg, A . and Gŕenman, S. (2000) Amplification and deletion of topoisomerase IIα gene are common in ErbB-2 amplified breast cancer and alter the sensitivity to doxorubicin. Am. J. Pathol. 156, 839-847
41. Zhou, Z., Zwelling, L. A., Kawakami, Y., An, T., Kobayashi, K., Herzog, C. and Kleinerman, E. S. (1999) Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res. 59, 4618-4624
42. Withoff, S., Keith, W. N., Knol, A. J., Coutts, J. C., Hoare, S. F., Mulder, N. H. and de Vries, E. G. (1996) Selection of a subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell line panel. Br. J. Cancer 74, 502-507